SLC5A2 and heart failure: For example, the EMPA-REG study, the first randomized clinical trial to examine an SGLT2 inhibitor, found that empagliflozin was associated with lower risks of heart failure hospitalization compared with placebo (HR 0.65; 95% CI 0.50–0.85) [13].